GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

46.55 -0.48 (-1.02%)

Official Closing Price Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

45 46 Next >

New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients

December 11, 2022

From GSK plc

Via Business Wire

Can Pfizer, Johnson & Johnson Continue Outperforming the Index?

December 09, 2022

Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months.

Via MarketBeat

France Health Body Advises Unfavorable Opinion Regarding Valneva's COVID-19 Vaccine ↗

December 08, 2022

Via Benzinga

GSK's Jemperli/Chemo Combo Shows Response Rate Of 46% In Head-To-Head Lung Cancer Trial ↗

December 07, 2022

Via Benzinga

GSK's Debt Overview ↗

December 06, 2022

Over the past three months, shares of GSK Inc. (NYSE:GSK) moved higher by 19.05%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its...

Via Benzinga

GSK Touts Encouraging Data From Mid-Stage Tuberculosis Program In Drug-Susceptible Patients ↗

November 14, 2022

Via Benzinga

GSK Limits Second-Line Maintenance Use Of Its Ovarian Cancer Drug To Some Populations ↗

November 11, 2022

Via Benzinga

Meta Criticized For Providing Extra Protection To Certain Users, Twitter HQ Bedrooms Under Regulatory Scrutiny, Juul Settles Over 5,000 Lawsuits: Top Stories Wednesday, Dec. 07 ↗

December 07, 2022

Benzinga

Via Benzinga

Relief To Pfizer, Sanofi As US Dismisses Several Lawsuits Associated With Zantac ↗

December 07, 2022

Via Benzinga

These 3 Stocks Escaped Tuesday's Market Downdraft ↗

December 06, 2022

Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.

Via The Motley Fool

Why GSK Plc And Sanofi SA Stock Are Shooting Higher ↗

December 06, 2022

Shares of GSK plc (NYSE: GSK) and Sanofi SA (NASDAQ: SNY) are trading higher going into the close of Tuesday's session after the companies reportedly won a Zantac product liability lawsuit.

Via Benzinga

Why Vir Biotechnology Jumped Nearly 19% Today ↗

November 04, 2022

A COVID-19 partnership with a major drugmaker is producing more fruit than expected.

Via The Motley Fool

Citing Efficacy, GSK Stops Two Pivotal UTI Antibiotic Trials Early ↗

November 03, 2022

Via Benzinga

GSK Surges As Shingles Vaccine Drives Commanding Third-Quarter Beat ↗

November 02, 2022

Shingrix and specialty medicines helped drive GSK's third-quarter growth.

Via Investor's Business Daily

Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing

December 06, 2022

From Singapore Economic Development Board (EDB)A*STAR

Via ACN Newswire

Cosmos Holdings May be a Long-Term Buy with Short-Term Risk

November 30, 2022

Cosmos Holdings stock is up 618% in November likely due to a short squeeze. This article explains why Cosmos Holdings may still be a good long-term investment

Via MarketBeat

Topics Intellectual Property

European Official Says COVID-19 Booster Uptake Disappointing In The Region ↗

November 25, 2022

Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather...

Via Benzinga

Researchers Working On Universal mRNA-Influenza Vaccine Aiming For Baseline Immune Memory For Diverse Strains ↗

November 25, 2022

Researchers are working on an experimental pan-influenza vaccine based on the famed mRNA technology to provide broad protection.

Via Benzinga

After Disappointing Confirmatory Study, GSK To Withdraw Approved Blood Cancer Drug In US ↗

November 22, 2022

Via Benzinga

Dividend Income Update October 2022 ↗

November 17, 2022

It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio.

Via Talk Markets

Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says ↗

November 16, 2022

Via Benzinga

FDA Moves Step Closer For Opioid Overdose Medication Access, Says Certain Naloxone Products Can Potentially Be Used In OTC Setting ↗

November 15, 2022

Via Benzinga

Peering Into GSK's Recent Short Interest ↗

November 15, 2022

GSK's (NYSE:GSK) short percent of float has fallen 11.39% since its last report. The company recently reported that it has 13.36 million shares sold short, which is 0.7% of all regular shares that are...

Via Benzinga

Daily Stock Analysis: GSK plc ↗

November 15, 2022

By my dogcatcher ideal, this is a likely time to buy GSK plc shares based on their dividends for the coming year 2022-23.

Via Talk Markets

Europe Approves Sanofi, GSK's Beta Variant Adapted COVID Shot As Booster ↗

November 10, 2022

Via Benzinga

Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles ↗

November 10, 2022

Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen.

Via Investor's Business Daily

GSK's Conditionally Approved Blood Cancer Drug Fails On Progression-Free Survival Goal Over Standard Care ↗

November 07, 2022

Via Benzinga

Week in Review: CBC Plans $137 Million Shanghai Biopharma Complex ↗

November 05, 2022

Deals, financings, trials and approvals in Chinese biotech/biopharma this week.

Via Talk Markets

Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth ↗

November 04, 2022

Sales of Vir Biotechnology and GSK's Covid antibody almost tripled sales estimates.

Via Investor's Business Daily

Moderna's Earnings Collapsed. Time to Sell? ↗

November 04, 2022

This drugmaker's bottom line fell down a deep hole in the third quarter and investors want to know if it's time to run for the hills.

Via The Motley Fool

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

45 46 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.